Shopping Cart
- Remove All
Your shopping cart is currently empty
Argentina
Australia
Austria
Belgium
Brazil
Bulgaria
Croatia
Cyprus
Czech
Denmark
Egypt
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Latvia
Lebanon
Malaysia
Malta
Morocco
Netherlands
New Zealand
Norway
Poland
Portugal
Romania
Singapore
Slovakia
Slovenia
Spain
Sweden
Switzerland
Taiwan,China
Thailand
Turkey
United Kingdom
United States
Other Countries
Select your Country or Region
AWL-II-38.3
Contact us for more batch information
Select Batch
Purity:99.87%
AWL-II-38.3
Catalog No. T38511Cas No. 1135205-94-5
AWL-II-38.3 is a highly effective inhibitor of EphA3, a receptor for ephrin-A. It demonstrates potent kinase inhibitory activity against EphA3 and does not show significant cellular activity against Src-family kinases or b-raf [1] [2].
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose. | Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $74 | In Stock | |
| 5 mg | $178 | In Stock | |
| 10 mg | $278 | In Stock | |
| 25 mg | $572 | In Stock | |
| 50 mg | $822 | In Stock | |
| 100 mg | $1,130 | In Stock | |
| 500 mg | $2,280 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $186 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "AWL-II-38.3"
Dasatinib monohydrate
Cited
T1448L863127-77-9
Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.
- $33
Size
QTY
CitedUniPR1449
T80896
UniPR1449 is an EphA2 receptor antagonist with a KD of 3.8±2.4 μM, which is significant in cancer pathophysiology [1].
- Inquiry Price
Size
QTY
UniPR1447
T808971809170-68-0
UniPR1447 is a dual antagonist for both EphA2 and EphB2 receptors, exhibiting an IC50 value of 6.6 μM against EphA2-ephrin-A1 binding [1].
- Inquiry Price
Size
QTY
Tesevatinib
TQ0166781613-23-8
Tesevatinib (XL-647) is an orally available, multi-target tyrosine kinase inhibitor (IC50s: 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, Flt4, and EphB4).
- $109
Size
QTY
ALW-II-49-7
T677361135219-23-6
ALW-II-49-7 is a selective and potent inhibitor of EphB2 kinase with an EC50 value of 40 nM in cell.
- $65
Size
QTY
Ehp-inhibitor-2
T5452861249-77-6
Ehp-inhibitor-2 is an Eph family tyrosine kinase inhibitor targeting Eph receptors.
- $39
Size
QTY
UniPR505
T733682938227-14-4In house
UniPR505 is a potent EphA2 antagonist (IC50: 0.95 µM), a novel 3α-carbamoyloxy derivative with antiangiogenic properties.
- $518
Size
QTY
Tivozanib
T2456475108-18-0
Tivozanib (KRN951) is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities.
- $34
Size
QTY
123C4
TP15612034159-30-1
123C4 is a novel, potent, and selective agonist of the tyrosine kinase EphA4 receptor.
- $147
Size
QTY
KYL acetate(676657-00-4 free base)
TP1895L1
KYL acetate is an EphA4 receptor tyrosine kinase inhibitor (Kd = 0.8 μM); inhibits EphA4-EphrinA5 interactions (IC50 = 6.34 μM). Prevents AβO induced synaptic damage, dendritic spine loss and prevents the blocking of LTP in hippocampal CA3-CA1 transmissions. Exhibits a long half life in cell culture media (8 and 12 hours in PC3 and C2C12 media respectively). Neuroprotective.
- $133
Size
QTY
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | AWL-II-38.3 is a highly effective inhibitor of EphA3, a receptor for ephrin-A. It demonstrates potent kinase inhibitory activity against EphA3 and does not show significant cellular activity against Src-family kinases or b-raf [1] [2]. |
| In vitro | AWL-II-38.3 fits to LIMK2 and LIMK1 ATP-binding and substrate-binding pockets [2] . |
| Molecular Weight | 469.42 |
| Formula | C23H18F3N5O3 |
| Cas No. | 1135205-94-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (95.86 mM), Sonication is recommended.  | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。 Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Dose Conversion
You can also refer to dose conversion for different animals. More
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.